{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:10:27Z","timestamp":1791472227085,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015626","name":"Melanoma Institute Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015626","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejca.2024.115055","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T01:57:09Z","timestamp":1727661429000},"page":"115055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy"],"prefix":"10.1016","volume":"212","author":[{"given":"Rachel","family":"Woodford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"McKeown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte L.","family":"Hoeijmakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Mangana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentia","family":"Dimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Allayous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Aya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marsiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Rayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Placzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Kessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egle","family":"Ramalyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqas","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Trojaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naima","family":"Benannoune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Roberts-Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Lebbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Haydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Arance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Hu-Lieskovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant A.","family":"Mcarthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Neyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serigne","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15_suppl","key":"10.1016\/j.ejca.2024.115055_bib1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9506","article-title":"CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma","volume":"39","author":"Wolchok","year":"2021","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2024.115055_bib2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.ejca.2024.115055_bib3","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage iii melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 Trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10336","key":"10.1016\/j.ejca.2024.115055_bib4","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ejca.2024.115055_bib5","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage iii\/iv melanoma: 5-year efficacy and biomarker results from checkMate 238","volume":"29","author":"Larkin","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.ejca.2024.115055_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133448","article-title":"Medical needs and therapeutic options for melanoma patients resistant to anti-pd-1-directed immune checkpoint Inhibition","volume":"15","author":"Hassel","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ejca.2024.115055_bib7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s11912-022-01288-y","article-title":"Treatment approaches for melanomas that relapse after adjuvant or neoadjuvant therapy","volume":"24","author":"Ng","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ejca.2024.115055_bib8","doi-asserted-by":"crossref","unstructured":"Owen C.N., Shoushtari A.N., Chauhan D., et al. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy(\u2606). Ann Oncol 2020;31(8):1075\u20131082.","DOI":"10.1016\/j.annonc.2020.04.471"},{"key":"10.1016\/j.ejca.2024.115055_bib9","doi-asserted-by":"crossref","first-page":"S665","DOI":"10.1016\/j.annonc.2023.09.2238","article-title":"1104P Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study","volume":"34","author":"Weichenthal","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.115055_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01448","article-title":"Outcomes with postrecurrence systemic therapy following adjuvant checkpoint inhibitor treatment for resected melanoma in checkmate 238","author":"Weber","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.115055_bib11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study","volume":"22","author":"Pires da Silva","year":"2021","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2024.115055_bib12","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.21.00079","article-title":"Pembrolizumab Plus ipilimumab following Anti-PD-1\/L1 failure in melanoma","volume":"39","author":"Olson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.115055_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2024.115055_bib14","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage iii melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.ejca.2024.115055_bib15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.22.00533","article-title":"Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915)","volume":"41","author":"Weber","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115055_bib16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejca.2023.03.011","article-title":"Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary?","volume":"186","author":"Varey","year":"2023","journal-title":"Eur J Cancer"},{"issue":"18","key":"10.1016\/j.ejca.2024.115055_bib17","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2024.115055_bib18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with <em>BRAF<\/em>-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.115055_bib19","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced <em>BRAF<\/em>V600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2024.115055_bib20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2024.115055_bib21","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2024.115055_bib22","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ejca.2024.115055_bib23","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2024.115055_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9522","article-title":"Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067","volume":"40","author":"Hodi","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2024.115055_bib25","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2024.115055_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924010219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924010219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T16:30:58Z","timestamp":1737649858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924010219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":26,"alternative-id":["S0959804924010219"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115055","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115055"}}